Intestinal fibrosis remains one of the largest clinical challenges in the field of inflammatory bowel diseases.1 More than one-half of the patients with Crohn’s disease develop clinically apparent fibrostenosis throughout their disease course, leading to hospitalizations, and the need for endoscopic interventions or surgery.1 Observational studies have taught us that despite the emergence of biologics, including anti-tumor necrosis factor antibodies, the rate of surgical interventions has only mildly decreased.